TABLE 1

Characteristics of the complete case weighted study population and asthma/chronic obstructive pulmonary disease (COPD) subpopulation

Total populationAsthma/COPD population
Subjects n5675846
Age years56±656±6
Male4436
BMI kg·m−226±427±5
Waist/hip ratio0.89±0.080.89±0.09
Physical activity MET·week–130 (16–50)31 (16–47)
Smoking
 Never3833
 Ex4650
 Current1617
Lung disease
 COPD, registry2.521.5
 COPD, questionnaire4.235.6
 Asthma, registry8.066.9
 Asthma, questionnaire4.437.4
 FEV1/FVC <0.714.832.5
Lung medication use
 Any bronchodilator5.340.2
 SABA2.115.3
 LABA0.43.1
 SAMA0.10.9
 LAMA0.96.7
 ICS1.813.7
 LABA+ICS3.829.4
 LABA+LAMA+ICS0.64.8
 Theophylline0.00.5
 Mucolytics0.41.3
 OCS0.41.8
Comorbidity
 Cardiovascular disease#6.07.0
 Diabetes mellitus3.54.7
 Depression+13.921.1
  Severe depression3.45.4

Data are presented as weighted mean±sd or median (interquartile range) for continuous outcomes and weighted proportion (%) for categorical outcomes, unless otherwise stated. BMI: body mass index; MET: metabolic equivalent of tasks; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; SABA: short-acting β-agonist; LABA: long-acting β-agonist; SAMA: short-acting muscarinic antagonist; LAMA: long-acting muscarinic antagonist; ICS: inhaled corticosteroid; OCS: oral corticosteroid. #: myocardial infarction, angina, congestive heart failure, peripheral vascular disease; : defined as self-reported diabetes mellitus type 1 or type 2 or medication use; +: defined as an Inventory of Depressive Symptomatology score ≥18 (severe depression as a score ≥29).